EP0119528B1 - Anticorps monoclonaux contre les antigènes du cancer du rein humain et procédé - Google Patents

Anticorps monoclonaux contre les antigènes du cancer du rein humain et procédé Download PDF

Info

Publication number
EP0119528B1
EP0119528B1 EP19840102265 EP84102265A EP0119528B1 EP 0119528 B1 EP0119528 B1 EP 0119528B1 EP 19840102265 EP19840102265 EP 19840102265 EP 84102265 A EP84102265 A EP 84102265A EP 0119528 B1 EP0119528 B1 EP 0119528B1
Authority
EP
European Patent Office
Prior art keywords
cells
renal
human renal
human
cell line
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
EP19840102265
Other languages
German (de)
English (en)
Other versions
EP0119528A2 (fr
EP0119528A3 (en
Inventor
Neil H. Bander
Carlos Cordon-Cardo
Connie L. Finstad
Willet F. Whitmore, Jr.
Myron R. Melamed
Herbert F. Oettgen
Lloyd J. Old
Yves Fradet
Kenneth O. Lloyd
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Memorial Sloan Kettering Cancer Center
Original Assignee
Memorial Sloan Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Memorial Sloan Kettering Cancer Center filed Critical Memorial Sloan Kettering Cancer Center
Publication of EP0119528A2 publication Critical patent/EP0119528A2/fr
Publication of EP0119528A3 publication Critical patent/EP0119528A3/en
Application granted granted Critical
Publication of EP0119528B1 publication Critical patent/EP0119528B1/fr
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3038—Kidney, bladder

Definitions

  • the present invention relates to the generation of monoclonal antibodies and their use in identifying or characterizing human renal cancer antigens. This is a useful diagnostic tool in the detection of renal cancer as well as the study of the nature of renal cancer.
  • Red blood cells, immunofluorescent, radioactive or enzymatic tagging agents can be bound to the highly specific antibodies using normal procedures, as required for indexing methods.
  • Cytotoxic agents can also be bound to the highly specific antibodies to produce so called "magic bullet" type therapeutic agents which selectively destroy the cell with which the specific antibody binds.
  • Köhler and Milstein introduced a procedure for the production of monoclonal antibodies (mAbs) using hybrid cells (hybridomas) which allows the production of almost unlimited quantities of antibodies of precise and reproducible specificity.
  • Conventional antisera produced by immunizing animals with tumor cells or other antigens, contain a myriad of different antibodies differing in their specificity and properties, whereas hybridomas produce a single antibody with uniform characteristics.
  • the Köhler-Milstein procedure entails the fusion of spleen cells from an immunized animal with an immortal myeloma cell line. From the fused cells (hybridomas), clones are selected that produce an antibody of the desired specificity. Each clone continues to produce only that one antibody.
  • hybridoma cells can be cultured indefinitely (or stored frozen in liquid nitrogen), a constant supply of antibody is assured.
  • Antibodies are proteins that have the ability to combine with and recognize other molecules, known as antigens. Monoclonal antibodies are no different from other antibodies except that they are very uniform in their properties and recognize only one antigen or a portion of an antigen known as a determinant.
  • the determinant recognized is an antigen on or in the cell which reacts with the antibody. It is through these cell antigens that a particular antibody recognizes, i. e. reacts with, a particular kind of cell. Thus the cell antigens are markers by which the cell is identified.
  • antigenic markers may be used to observe the normal process of cell differentiation and to locate abnormalities within a given cell system.
  • the process of differentiation is accompanied by changes in the cell surface antigenic phenotype, and antigens that distinguish cells belonging to distinct differentiation lineages or distinguish cells at different phases in the same differentiation lineage may be observed if the correct antibody is available.
  • Initial recognition of differentiation antigens came about through analysis of surface antigens of T-cell leukemias of the mouse and the description of the TL, Thy-1, and Lyt series of antigens. (Old, Lloyd J., Cancer Research, 41, 361-375, February 1981).
  • T-cell differentiation antigens were greatly simplified by the availability of normal T cells and B cells of mouse and man and is relatively advanced; US-Patents 4,361,549-550; 4,364,932-37 and 4,363,799 concerning mAb's to Human T-cell antigens). Little is known about differentiation antigens displayed on normal and neoplastic cells belonging to other lineages.
  • hybrid cell lines can be successful or not depending on such experimental factors as nature of the inoculant, cell growth conditions, hybridization conditions etc. Thus it is not always possible to predict successful hybridoma preparation of one cell line although success may have been achieved with another cell line.
  • gp160, S 25 , and gp120r can be distinguished on the basis of differential expression on a panel of cultured renal cancers and normal kidney epithelium and fetal kidney cells.
  • Glycoproteins bearing gp120r share a determinant with renal gp120nr (as indicated by sequential precipitations with monoclonal antibodies that detect gp120r and gp120nr), but gp120nr is found on a broader range of cell types, including fibroblasts and cell lines derived from ovarian, bladder, and colon cancers.
  • the two other new systems, gp115 and Vi have characteristics of broadly occurring differentiation antigens but can be distinguished from each other and from gp120nr by differences in molecular weight, heat stability (V i is a heat-stable determinant), and differential expression on cell types of diverse origin.
  • these 12 antigenic systems can be further classified into three groups: (i) those with characteristics of restricted differentiation antigens (e. g., the renal-specific gp160, S 25 , and gp120r antigens and the R 24 antigen of melanoma and melanocytes), (ii) more broadly represented differentiation antigens (e. g., gp95, gp150, M 19 , pg120nr, and Vi, and (iii) antigens expressed by every human cell type tested (e. g., 0 5 species antigen).
  • restricted differentiation antigens e. g., the renal-specific gp160, S 25 , and gp120r antigens and the R 24 antigen of melanoma and melanocytes
  • differentiation antigens e. g., gp95, gp150, M 19 , pg120nr, and Vi
  • antigens expressed by every human cell type tested e. g., 0
  • serological probes provided by the invention can identify kidney-specific antigens and are of particular interest in the study of kidney structure and function.
  • some of the more broadly reacting antibodies are useful in studying other tumors - e. g. V 1 which distinguishes astrocytomas from melanomas.
  • the present invention relates to a monoclonal antibody and to the corresponding monoclonal antibody-producing hybridoma cell line obtainable by fusing a myeloma derived cell strain and splenocytes derived from BALB/c mice immunized with human normal renal epithelial cells, said monoclonal antibody being capable of recognizing human renal epithelial cancer cells. It especially relates to a monoclonal antibody which recognizes the human renal cell antigen gp140, said antigen gp140 being recognizable by the monoclonal reference antibody F23 (ATCC HB 8231).
  • the new mAb, F23 is described below.
  • F23 is part of a panel of monoclonal antibodies of renal origin used to detect renal cancer cells and antigens. This panel serves an important diagnostic function.
  • the mAbs therein subset renal tumors and subset the normal nephron.
  • the mAbs define renal antigens on normal cells, presumably differentiation antigens; and define renal antigens present on tumors, thus distinguishing normal and cancerous renal cells.
  • the monoclonal antibody designated F23 recognizes human renal cells and is produced by the hybridoma cell line deposited with the ATCC under Accession No. HB 8231.
  • the present invention also relates to a method for differentiating between normal and malignant human renal cells which comprises contacting a human renal sample with a plurality of monoclonal antibodies each of which is different and each of which is produced by a hybridoma cell line formed by fusing a myeloma derived cell strain and splenocytes derived from BALB/c mice immunized with established culture lines from the group of human epithelial renal cancer or normal human renal epithelial cells under suitable conditions so as to form a complex between each antibody and an antigen, detecting the presence of any so formed complex, the absence of any complex indicating normal renal cells and the presence of any complex indicating the presence of malignant human renal cells.
  • the plurality of monoclonal antibodies can be selected from the group consisting of F 23 , M 2 , S 8 and S 21 .
  • the above method may further comprise contacting a human renal sample with a plurality of monoclonal antibodies selected from the group consisting of M 1 , S 4 , S 6 , S 7 , S 22 , S 23 , S 24 , S 25 , S 26 , S 27 and V i . It may be used as an assay for the malignant potential of human renal tumors.
  • M-MHA mouse mixed hemadsorption assay
  • Culture supernatants were monitored for antibody activity on a panel of cultured cells consisting of two renal cancer cell lines (including the immunizing line), AJ astrocytoma, SK-MEL-33 and -37 melanomas, Me-180 cervix cancer, WI-38 fetal cells, VERO adult and fetal kidney epithelium, and fetal brain cells.
  • Antibody subclass was determined by double diffusion in agar with anti-lg heavy chain specific reagents (Bionetics, Kensington, M. D.). Cultures of cloned hybridomas were injected subcutaneously into nu/nu mice (Swiss background) and were also stored in liquid nitrogen. Sera from mice with progressively growing tumors were collected, stored at -70°C, and used for serological and biochemical characterization.
  • Immunoprecipitation was carried out by mixing a portion of the cell extract (1 x 10 5 cpm) with 2 ⁇ l of mouse serum and 20 ⁇ l of rabbit anti-mouse Ig serum (Cappel Laboratories, Cochranville, PA) in Tris buffer). Immune complexes were isolated by using Staphylococcus aureus and analyzed by NaDodS0 4 / polyacrylamide gel electrophoresis as described (Dippold et al (supra)). ( 35 S) Methionine-labeled samples were immunoprecipitated in a similar manner, except that Sepharose-rabbit F (ab') 2 anti-mouse Ig was used for isolating the complexes.
  • Sepharose-rabbit F (ab') 2 anti-mouse Ig was used for isolating the complexes.
  • the serological specificity of these antibodies was tested on a panel of 47 established cell lines (13 renal cancers, 5 melanomas, gliomas neuroblastomas, 15 epithelial cancers 5 B-cell lines K562 (an erythroid leukemia), 2 T-cell lines (MOLT-4 and T-45), and monkey kidney cells (VERO)).
  • the antibodies were tested against short-term cultures of normal kidney epithelium, fibroblasts, and fetal tissues (brain, fibroblasts, and kidney). Human, sheep, rat and bovine erythrocytes were also examined. In most cases, serological analysis consisted of both direct and absorption tests.
  • gp160 Antigenic System Five Abs in this series (S 4 , S 7 , S 11 , S 24 , and Mi) identify a 160,000-dalton glycoprotein that showed a high degree of specificity for human kidney cells. gp160 is a rather basic component with pl 7.5. By M-MHA tests, gp16 0 could be demonstrated on all cultures of normal kidney epithelium, 2 of 3 cultures of fetal kidney, and 7 of 13 established lines of renal cancer (Table 2). These results were confirmed in absorption tests. No other cell type, normal or malignant, was found to express the gp160 antigen, including VERO, a cell line derived from monkey kidney.
  • VERO a cell line derived from monkey kidney.
  • S 25 Antigenic System The antigen detected by AD S 25 also is restricted to human cells of renal origin (Table 2).
  • the S 25 determinant is heat labile, suggesting that it resides on a protein or glucoprotein, but Ab S 25 did not precipitate any detectable component from ( 35 S) methionine-labeled or ( 3 H) glucosamine-labeled SK-RC-7 cells.
  • Comparison of the S 25 and the gp160 phenotypes of different renal cancer lines and cultures of normal kidney clearly distinguished these two systems. For example, SK-RC-6 and A-498 are gp160 / S25" and SK-RC-8 is gp160- / S 25 + , whereas five of these cultures lacked S 25 expression.
  • gp120r identified by Ab S 23
  • Ab S 6 The other gp120 epitope, gp120nr, identified by Ab S 6 , was found on a wide range of cultured cells including fetal and adult fibroblasts and cell lines derived from ovarian, bladder and colon cancers.
  • gp120r and gp120nr determinants differ in their expression on renal cancer cell lines: all cell lines carry the gp120nr epitope,whereas SK-RC-2 -21, -29, and Caki-1 lack gp120r determinants.
  • Ab S 23 for cells of renal origin resembles the reactivity of Ab S 25 and, most particularly, antibodies identifying the gp160 system.
  • these three kidney-specific antigenic systems can be distinguished on the basis of absorption analysis with selected normal or malignant kidney cells - e. g., SK-RC-6 and A-498 are are gp160 + /S 25 -/gp120r + ; fetal kidney is gp160 or -/S 25 + /gp120r - .
  • gp115 Antigenic System Ab S 22 immunoprecipitated a 115,000-dalton glycoprotein from ( 3 H) glucosamine- or ( 35 S) methionine-labeled lysates of SK-RC-7 cells under both reduced and nonreduced conditions (Fig. 1). In direct M-MHA tests, high reactivity (titers, 1-10,000 x 10- 3 ) was restricted to certain renal cancer cells and normal kidney epithelium (Table 2). Absorption analysis, however, revealed that the gp115 antigen was expressed by various cell types.
  • V 1 Antigenic System Ab V 1 did not immunoprecipitate any labeled component from ( 3 H) glucosamine-or ( 35 S) methionine-labeled lysates of SK-RC-7 cells. Absorption tests indicated that the antigen is heat stable (5 mins. at 100°C), suggesting that it is a glycolipid.
  • Two features of the V 1 (Table 2) system are of particular interest: (a) it identifies a subset of bladder and breast cancers which do not express V 1 , and (b) V 1 is not found on astrocytomas, whereas melanomas are strong V 1 expressors. This clear distinction between astrocytomas and melanoma, whose embryonic derivations are closely related, has not been seen with other Abs.
  • Ab S 21 immunoprecipitated a 45,000- and a 12,000-dalton component from ( 35 S) methionine-labeled SK-RC-7 lysates.
  • the determinant detected by Ab S 21 in direct and absorption tests was present on virtually every human cell type with the exception of human erythrocytes (Table 2).
  • the only cell lines not reactive with Ab S 21 in direct MHA tests were ME-180 and SK-MEL-19; the SK-MEL-19 melanoma cell line is known from previous work to express little or no HLA-A, -B, -C antigens.
  • a and B Blood Group Antigens Two of the three renal cancer lines used for immunization (Table 1) express blood group A and B antigens on their cell surfaces; SK-RC-7 is B and SK-RC-28 is A . SK-RC-6 is derived from a type O individual and is negative for A and B reactivities. To detect Abs reacting with blood group antigens, hybridoma supernatants were screened for hemagglutinating antibody by using A, B, AB, or O erythrocytes.
  • the hemagglutination titer of Ab M 2 (nu/nu serum) for A and AB erythrocytes was 10- 4 ; B erythrocytes were not agglutinated by Ab M 2 .
  • the hemagglutination titer of Ab S 8 (nu/nu serum) for B and AB erythrocytes was 4 x 10- 5 ; A type erythrocytes were not agglutinated by Ab S 8 .
  • Table 3 summarizes inhibition tests with Ab S 8 and Ab M 2 using glycoprotein and mucin extracts having A, B, H and Lewis a blood group reactivity. The results confirmed the A specificity of Ab M 2 and the B specificity of Ab S 8 .
  • the present invention describes a new monoclonal antibody, F 23 , a gamma sub 2A (y 2A) immunoglobulin (Ig).
  • mAb S 4 was in that same class of Ig while S 25 , S 22 , S 23 , S 6 , S 27 , V 1 and S 2 , belonged to immunoglobulin class gamma sub one ( ⁇ 1 ) and M 2 and S 8 to Ig class mu(u).
  • F 23 recognizes a new antigenic system on human renal cells glycoprotein (gp) 140.
  • F 23 is derived from a hybridoma cell line wherein normal human epithelial cells are the immunogen. Yet antibodies to renal tumors are made by this invention. This is an unexpected result.
  • F 23 recognizes human renal cancer cell lines. Of 25 cell lines tested, F 23 is positioned for 19 of those. 33 human renal cell lines were studied. F 23 also recognizes some poorly differentiated renal carcinomas and some renal carcinomas with papillary differentiation with its best reaction with well differentiated renal carcinomas i. e. F 23 subsets renal carcinomas and can be used to assay for the malignant potential of renal tumors. Frozen renal carcinoma section for over 20 different human specimens were tested as well. Comparison of frozen sections and tissue culture lines established from the same specimens reveals that for most antigens, expression is consistent in vivo and in vitro. See tables I & II.
  • Some antigens may be either induced or suppressed in tissue culture. This characteristic must be determined for each antigen prior to extrapolating results between in vivo and in vitro systems.
  • F 23 mAb must be added to the mAb panel for human renal cancer which to date includes then F 23 , M 1 , M 2 , S 1 , S 4 , S 6 , S 7 , Sg, S11, S 21 , S 22 , S 23 , S 24 , S 25 , S 26 , S 27 , V 1 and V 2 .
  • This entire array of mAbs is used to diagnose renal cancer. A specimen tissue, body waste or fluid or exudate is contacted separately with each of the above mAbs in a screening test for a positive reaction.
  • F 23 also gives a positive reaction with two cell lines of normal kidney epithelium. However, F 23 did not react with normal human A, B or D erythrocytes by the absorption test. In frozen reactions, F 23 reacted with normal kidney and proximal tubule in fetal as well as adult specimens. F 23 showed a positive reaction in brain and neurons. Table II.
  • Normal proximal tubule cells express gp antigens at consistent levels (gp160, gp120r and gp115) whereas only 5/31 tumors expressed all three antigens. 26 tumors did not express these antigens and 8 of the tumor cell lines tested were negative for gp140. In further differentiating normal versus malignant cells it is noted that when one of the gp antigens (160, 120r or 115) was present in a tumor levels of expression of the antigen ranged as high as 10,000 x normal. Results show antigen expression correlated with the malignant potential of these tumors.
  • the invention involves the use of a micro-organism (monoclonal antibody), which is deposited at the American Type Culture Collection (ATCC)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Claims (14)

1. Lignée cellulaire d'hybridome produisant un anticorps monoclonal pouvant être obtenu par la fusion d'une souche cellulaire dérivée d'un myélome et de splénocytes dérivés de souris BALB/c immunisées avec des cellules éphitéliales rénales normales humaines, l'anticorps monoclonal pouvant reconnaître les cellules du cancer épithélial rénal humain.
2. Anticorps monoclonal produit par la lignée cellulaire de l'hybridome selon la revendication 1.
3. Anticorps monoclonal qui reconnaît l'antigène des cellules rénales humaines gp140, cet antigène gp140 pouvant être reconnu par l'anticorps de référence monoclonal F23 (ATCC HB 8231).
4. Anticorps monoclonal désigné F23 qui reconnaît les cellules rénales humaines et qui est produit par la lignée cellulaire de l'hybridome déposée à l'ATCC sous le numéro d'accession HB 8231.
5. Lignée cellulaire d'hybridome selon la revendication 1 qui produit l'anticorps monoclonal désigné F23 et déposée à l'ATCC sous le numéro d'accession HB 8231.
6. Procédé pour former une lignée cellulaire d'hybridome produisant l'anticorps monoclonal en fusionnant une souche cellulaire dérivée du myélome avec des splénocytes dérivés de souris BALB/c immunisées avec des cellules épithéliales rénales humaines normales.
7. Lignée cellulaire d'hybridome formée par le procédé selon la revendication 6.
8. Anticorps monoclonaux produits par la lignée cellulaire d'hybridome de la revendication 7.
9. Procédé pour la différenciation entre des cellules rénales humaines normales et malignes qui comprend les étapes consistant à mettre en contact un échantillon rénal humain avec plusieurs des anticorps monoclonaux dont chacun est différent et dont chacun est produit par une lignée cellulaire d'hybridome formée par la fusion d'une souche cellulaire dérivée d'un myélome et de splénocytes dérivés de souris BALB/c immunisées avec des lignées de culture établies à partir du groupe de cellules du cancer rénal épithélial humain ou de cellules épithéliales rénales humaines normales dans des conditions appropriées de façon à former un complexe entre chaque anticorps et un antigène, à détecter la présence de tout complexe ainsi formé, l'absence de tout complexe indiquant des cellules rénales normales et la présence de tout complexe indiquant la présence de cellules rénales humaines malignes.
10. Procédé selon la revendication 9, dans lequel on choisit plusieurs des anticorps monoclonaux dans le groupe constitué par F23, M2, S8 et 821.
11. Procédé selon la revendication 10, qui comprend de plus l'étape consistant à mettre en contact un échantillon rénal humain avec plusieurs des anticorps monoclonaux sélectionnés dans le groupe constitué par Mi , S4, Ss, S7, S22, S23, S24, S25, S26, S27, et V1.
12. Procédé selon la revendication 10, dans lequel le procédé est utilisé comme analyse pour le potentiel malin, des tumeurs rénales humaines.
13. Complexe anticorps/antigène comprenant des anticorps monoclonaux selon l'une quelconque des revendications 2 à 4 et 8 et des cellules rénales humaines.
14. Complexe anticorps/antigène selon la revendication 13 dans lequel les anticorps monoclonaux sont liés aux composants cellulaires rénaux humains antigènes.
EP19840102265 1983-03-11 1984-03-02 Anticorps monoclonaux contre les antigènes du cancer du rein humain et procédé Expired EP0119528B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47422483A 1983-03-11 1983-03-11
US474224 1983-03-11

Publications (3)

Publication Number Publication Date
EP0119528A2 EP0119528A2 (fr) 1984-09-26
EP0119528A3 EP0119528A3 (en) 1987-06-03
EP0119528B1 true EP0119528B1 (fr) 1992-05-13

Family

ID=23882671

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19840102265 Expired EP0119528B1 (fr) 1983-03-11 1984-03-02 Anticorps monoclonaux contre les antigènes du cancer du rein humain et procédé

Country Status (4)

Country Link
EP (1) EP0119528B1 (fr)
JP (1) JPH0734741B2 (fr)
CA (1) CA1221648A (fr)
DE (1) DE3485712D1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7393823B1 (en) 1999-01-20 2008-07-01 Oregon Health And Science University HER-2 binding antagonists
US7396810B1 (en) 2000-08-14 2008-07-08 Oregon Health Sciences University Compositions and methods for treating cancer by modulating HER-2 and EGF receptors
US7625859B1 (en) 2000-02-16 2009-12-01 Oregon Health & Science University HER-2 binding antagonists

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4713352A (en) * 1981-08-31 1987-12-15 Sloan-Kettering Institute For Cancer Reseach Monoclonal antibody panel for early diagnosis and therapy of renal carcinoma
JPS61104783A (ja) * 1985-09-10 1986-05-23 Wakunaga Seiyaku Kk 抗ヒト癌モノクロ−ナル抗体生産性ハイブリド−マ
JPS61103837A (ja) * 1984-10-26 1986-05-22 Wakunaga Seiyaku Kk 抗ヒト癌モノクロ−ナル抗体
JP2529836B2 (ja) * 1986-10-31 1996-09-04 元 稲本 モノクロ−ナル抗体を用いた尿中腎抗原の測定による腎障害の診断方法
WO1988008854A1 (fr) * 1987-05-06 1988-11-17 Egbert Oosterwijk Anticorps monoclonaux contre le carcinome des cellules renales
JP2561217B2 (ja) * 1993-10-27 1996-12-04 元 稲本 尿中腎抗原の測定による腎障害の診断方法に用いるモノクローナル抗体を産生するハイブリドーマ
FR2793497B1 (fr) * 1999-05-10 2003-04-18 Centre Nat Rech Scient Anticorps monoclonal dirige contre les cellules de carcinome renal humain

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4650756A (en) * 1981-08-31 1987-03-17 Sloan Kettering Institute For Cancer Research Monoclonal antibodies to cell surface antigens of human renal cancer
EP0143367A3 (fr) * 1983-11-30 1987-11-25 Sloan-Kettering Institute For Cancer Research Procédé de production d'anticorps monoclonaux pour le diagnostic et la thérapie du cancer

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7393823B1 (en) 1999-01-20 2008-07-01 Oregon Health And Science University HER-2 binding antagonists
US7625859B1 (en) 2000-02-16 2009-12-01 Oregon Health & Science University HER-2 binding antagonists
US7935784B2 (en) 2000-02-16 2011-05-03 Oregon Health And Science University HER-2 binding antagonists
US7396810B1 (en) 2000-08-14 2008-07-08 Oregon Health Sciences University Compositions and methods for treating cancer by modulating HER-2 and EGF receptors

Also Published As

Publication number Publication date
DE3485712D1 (de) 1992-06-17
CA1221648A (fr) 1987-05-12
JPH0734741B2 (ja) 1995-04-19
EP0119528A2 (fr) 1984-09-26
JPS59219299A (ja) 1984-12-10
EP0119528A3 (en) 1987-06-03

Similar Documents

Publication Publication Date Title
Ueda et al. Cell surface antigens of human renal cancer defined by mouse monoclonal antibodies: identification of tissue-specific kidney glycoproteins.
US4650756A (en) Monoclonal antibodies to cell surface antigens of human renal cancer
US4713352A (en) Monoclonal antibody panel for early diagnosis and therapy of renal carcinoma
EP0119556B1 (fr) Anticorps monoclonaux contre le cancer du colon humain et méthode
Meeker et al. A unique human B lymphocyte antigen defined by a monoclonal antibody
EP0201509B1 (fr) Anticorps monoclonal d'un antigene associe a une tumeur cancereuse chez l'homme
EP0079696B1 (fr) Anticorps monoclinaux spécifiques pour la glycoprotéine réceptrice de la transférinne humaine
Cairncross et al. Cell surface antigens of human astrocytoma defined by mouse monoclonal antibodies: identification of astrocytoma subsets.
US4666845A (en) Monoclonal antibodies to ovarian, cervical and uterine human cancers and method of diagnosis
Kennel et al. Analysis of surface proteins of mouse lung carcinomas using monoclonal antibodies
US4643971A (en) Monoclonal antibodies to human bladder and ureter cancers and method
US4626507A (en) Hybridomas producing monoclonal antibodies specific for a human cell surface glycoprotein
EP0119528B1 (fr) Anticorps monoclonaux contre les antigènes du cancer du rein humain et procédé
US4970299A (en) Monoclonal antibodies selective for prostate cancer
EP0199141A2 (fr) Anticorps monoclonaux contre le cancer gastro-intestinal humain
US4882270A (en) Monoclonal antibodies to placental isoferritin for use in detecting oncofetal ferritin associated with breast cancer and Hodgkins disease
US4678747A (en) Monoclonal antibodies for detection of an H (O) blood group antigen
US4710457A (en) Monoclonal antibody for human hematopoietic glycoproteins and method
US4642291A (en) Cell surface antigens of human astrocytoma
Saji et al. Monoclonal antibodies specific for two different histological types of human lung carcinoma
Girardet et al. Identification by a monoclonal antibody of a glycolipid highly expressed by cells from the human myeloid lineage
US4935344A (en) Method for characterizing types of renal carcinoma and prognosis
EP0060871B1 (fr) Anticorps monocloniques specifiques des glycoproteines de surface des cellules hemopoietiques humaines
EP0184370A2 (fr) Anticorps monoclonal spécifique d'un antigène cytoplasmique de tumeur mammaire
EP0143367A2 (fr) Procédé de production d'anticorps monoclonaux pour le diagnostic et la thérapie du cancer

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Designated state(s): DE FR GB

RIN1 Information on inventor provided before grant (corrected)

Inventor name: FRADET, YVES

Inventor name: OLD, LLOYD J.

Inventor name: OETTGEN, HERBERT F.

Inventor name: MELAMED, MYRON R.

Inventor name: WHITMORE, WILLET F., JR.

Inventor name: FINSTAD, CONNIE L.

Inventor name: CORDON-CARDO, CARLOS

Inventor name: BANDER, NEIL H.

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): DE FR GB

17P Request for examination filed

Effective date: 19871030

17Q First examination report despatched

Effective date: 19890413

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): DE FR GB

REF Corresponds to:

Ref document number: 3485712

Country of ref document: DE

Date of ref document: 19920617

ET Fr: translation filed
PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed
PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 19980209

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 19980220

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 19980225

Year of fee payment: 15

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19990302

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 19990302

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19991130

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20000101